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Determinants of survival and attempted resection in patients with non-metastatic 
pancreatic cancer: an Australian population-based study. 
EA Burmeister, M Waterhouse, SJ Jordan , DL O’Connell, ND Merrett, D Goldstein, D 
Wyld, V Beesley,  H Gooden, M Janda, RE Neale 
 
ABSTRACT 
Background 
There are indications that pancreatic cancer survival may differ according to sociodemographic 
factors, such as residential location. This may be due to differential access to curative resection. 
Understanding factors associated with the decision to offer a resection might enable strategies 
to increase the proportion of patients undergoing potentially curative surgery.  
Methods 
Data were extracted from medical records and cancer registries for patients diagnosed with 
pancreatic cancer between July 2009 and June 2011, living in one of two Australian states. 
Among patients clinically staged with non-metastatic disease we examined factors associated 
with survival using Cox proportional hazards models. To investigate survival differences we 
examined determinants of : 1) attempted surgical resection overall; 2) whether patients with 
locally advanced disease were classified as having resectable disease; and 3) attempted 
resection among those considered resectable.  
Results 
Data were collected for 786 eligible patients. Disease was considered locally advanced for 561 
(71%) patients, 510 (65%) were classified as having potentially resectable disease and 365 
(72%) of these had an attempted resection. Along with age, comorbidities and tumour stage, 
increasing remoteness of residence was associated with poorer survival. Remoteness of 
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residence and review by a hepatobiliary surgeon were factors influencing the decision to offer 
surgery. 
Conclusions 
This study indicated disparity in survival dependent on patients’ residential location and access 
to a specialist hepatobiliary surgeon. Accurate clinical staging is a critical element in assessing 
surgical resectability and it is therefore crucial that all patients have access to specialised 
clinical services. 
 
Keywords: Cancer care, Health service utilisation, Pancreatic cancer, Surgery, Survival. 
INTRODUCTION 
Pancreatic cancer is the 10th most commonly diagnosed cancer in more developed regions of 
the world. However, it has the worst prognosis of any cancer, with a five-year relative survival 
of less than 5%, so is the 4th most common cause of cancer death.1 Although survival rates have 
improved slightly over the past decade, current projections suggest that it will be the second 
leading cause of cancer death in the United States within 10 years.2 
Worse survival has been observed for patients who live outside metropolitan areas,3 have low 
socioeconomic status and who are elderly.4 While patient factors such as frailty and 
comorbidities may be partially responsible for these survival differences, isolation and access 
to quality care may also play a role. This access to care is becoming increasingly important as 
vascular reconstruction becomes more commonplace in major centres, particularly in 
combination with neoadjuvent therapies for borderline resectable tumours. Multimodality 
therapy which includes complete surgical removal of the tumour currently provides the only 
potentially curative therapeutic option,5-7 improving five-year survival to about 20%.8-10 
However, due to the proximity of the pancreas to large vessels and organs, assessment of 
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resectability is challenging and surgical resection itself is technically challenging.11   National 
Cancer Comprehensive Network (NCCN) guidelines therefore recommend multidisciplinary 
consultation when determining potential resectability,12 with the involvement of a skilled, 
specialised hepatobiliary surgeon as an integral part of the team.13, 14 International data show 
that resection rates are influenced by ethnicity, insurance status, marital status, education level, 
socioeconomic status and geographical distance from large metropolitan areas.15-18 There are 
indications that this may be related to the expertise at the facility where patients are being 
staged.19  
Understanding factors that influence survival and that are associated with surgical resection 
may enable implementation of strategies to ensure all patients with pancreatic cancer who are 
suitable for surgery are indeed offered such potentially curative surgery as part of their 
management. Using data from an Australian population-based study of patients clinically 
staged as having non-metastatic pancreatic cancer, our aim was to investigate survival 
according to patient, tumour and health-service factors and to examine components associated 
with determination of resectability and whether or not resection was attempted.  
METHODS 
Study population and data collection 
Data collection and regulatory approvals for the study have been described previously.20 
Briefly, the study included patients aged ≥18 years who were notified to the Queensland Cancer 
Registry between 1 July 2009 and 30 June 2011 or to the New South Wales Cancer Registry 
between 1 July 2009 and 31 December 2010 with a diagnosis of pancreatic ductal 
adenocarcinoma. We obtained demographic and initial diagnosis information from the cancer 
registries; trained research nurses collected detailed clinical data from medical records. Date 
of death was obtained from medical records or cancer registries. As all patients with metastatic 
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disease on initial clinical staging are unsuitable for curative resection, analyses were restricted 
to patients with no evidence of metastatic disease on clinical staging. 
Outcomes 
The main outcomes were one- and two-year mortality, defined as death of any cause within 
one and two years of diagnosis respectively, and survival time. Survival time was defined as 
the number of months from diagnosis until death or, for patients still alive, until date of last 
follow-up (February 2014). The date of diagnosis was taken as either the date of first diagnosis 
on imaging or histology/cytology, whichever came first.  
To investigate survival differences, we examined factors associated with: (1) attempted 
surgical resection for all patients with non-metastatic disease; (2) whether patients with locally 
advanced disease were classified as having potentially resectable disease (restricted to this 
patient group as disease confined to the pancreas is automatically classified as resectable); and 
(3) attempted resection for those considered resectable. Whether or not a tumour was 
considered to be locally advanced or resectable was extracted from medical specialist or 
multidisciplinary team (MDT) meeting notes.  
Factors of interest 
Patient characteristics: The patient factors of interest included age at diagnosis, sex, Eastern 
Cooperative Oncology Group (ECOG) performance status and Charlson comorbidity index.21 
Based on area of residence at the time of diagnosis, each person was allocated a socio-economic 
index for areas (SEIFA)22 score and Accessibility/Remoteness Index of Australia (ARIA)23 
category. For analysis we grouped the SEIFA score into quintiles and collapsed the ARIA into 
three groups: major city; inner regional; and outer regional/remote/very remote. 
Tumour characteristics: Tumour factors included the site within the pancreas 
(head/neck/uncinate process, body, tail or multiple/other) and clinical stage of the tumour 
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(confined to the pancreas or locally advanced disease). Locally advanced disease was defined 
as localised (non-metastatic) disease spread beyond the pancreas.  
Health service characteristics: Health-service factors included the type of specialist first seen, 
the volume (according to the number of patient presentations in the study) of the facility where 
the patient was first treated as an inpatient, whether the patient was reviewed by a MDT and if 
they were assessed by a hepatobiliary surgeon. A hepatobiliary surgeon was defined as a 
surgeon who had undergone recognised specialised hepatobiliary surgery training and/or was 
recognised by their peers as an experienced hepatobiliary surgeon. Receipt of any 
chemotherapy was also included in the analysis of the mortality and survival outcomes. 
Associations between investigations performed to clinically stage the patient’s tumour 
including computerised tomography (CT) (+/- pancreas protocol), endoscopic ultrasound 
(EUS), endoscopic retrograde cholangio-pancreatography (ERCP), magnetic resonance 
imaging (MRI) or cholangiopancreatography (MRCP), and laparoscopy, and each of 
resectability and attempted resection were evaluated. 
Statistical analysis 
Survival curves were generated and median survival was estimated using Kaplan-Meier 
methods, and the median time of follow-up was estimated using reverse Kaplan-Meier 
methods.24 The associations between all patient, tumour and health-care factors and one- and 
two-year mortality were examined using logistic regression and the crude odds ratios (ORs) 
were estimated. Hazard ratios (HRs) for overall survival were estimated using Cox proportional 
hazards models. All patient and tumour factors were then included in multivariable models to 
estimate adjusted odds ratios (AORs) or hazard ratios (AHRs). Models examining health-
service factors included all patient and tumour factors and the receipt of chemotherapy.  
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Associations between patient/tumour/health-service factors and each of (1) attempted 
resection; (2) whether or not the tumour was staged as potentially resectable for patients with 
locally advanced disease; and (3) whether or not a resection was attempted among those who 
were considered resectable were examined using multivariable logistic regression. To 
understand associations between place of residence, age and other patient and health-service 
factors, Chi-squared tests were used. 
Hierarchical mixed effects models, with hospital as a random intercept, were used to adjust for 
the effects of clustering within hospitals when assessing associations between the outcomes of 
interest and hospital volume.  
Statistical analyses were performed in Stata13 (Statacorp, Texas). All p-values are two-sided 
and we considered  p < 0.05 as an indication of statistical significance. 
RESULTS 
Patient characteristics and disease stage 
Overall, 786 patients (44%) were clinically staged as having non-metastatic disease at 
diagnosis. The median age of these participants was 70 years (range 29 - 99) and 54% were 
men. The majority (69%) lived in major cities, 21% resided in inner regional areas and 10% in 
outer regional or remote locations. Disease was considered locally advanced for 561 (71%) 
patients. About two-thirds (n = 510; 65%) were classified as having potentially resectable 
disease after staging (225 with disease confined to the pancreas and 285 with locally advanced 
disease) and resection was attempted for almost three-quarters (n = 365; 72%) of these.  
Mortality and survival 
Median survival was 10 months and the proportions of patients who died within one and two 
years of diagnosis were 58% (n = 454) and 80% (n = 626) respectively.  
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Increasing age, comorbidities, low performance status, more advanced clinical stage of disease 
and tumours in the body of the pancreas were associated with higher mortality and poorer 
survival outcomes (Table 1, Figure 1).  
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Table 1: Associations between patient, tumour and health-service characteristics and 1- and 2-year mortality and survival for patients diagnosed 
with non-metastatic disease (n = 786) 
   1-year mortalitya  2-year mortalitya  Overall survivalb 
Exposure variable 
Nc 
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI) 
 % 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI) 
 Median 
(months) 
Crude HR 
(95% CI) 
Adjusted HRd 
(95% CI) 
Patient / tumour factors             
Age at diagnosis, years             
< 60 141 38.3 1.00 1.00  66.7 1.00 1.00  13.9 1.00 1.00 
60 - 69 218 48.2 1.50 (0.97, 2.30) 1.34 (0.84, 2.15)  76.2 1.60 (1.00, 2.56) 1.45 (0.86, 2.45)  13.0 1.20 (0.95, 1.52) 1.05 (0.83, 1.34) 
70 - 79 223 65.8 2.72 (1.76, 4.20) 2.31 (1.44, 3.73)  79.8 1.98 (1.22, 3.19) 1.69 (0.98, 2.91)  8.4 1.57 (1.24, 1.98) 1.33 (1.04, 1.69) 
≥ 80 204 76.0 5.10 (3.19, 8.13) 3.48 (2.05, 5.91)  92.2 5.88 (3.16, 10.91) 3.99 (1.94, 8.24)  5.0 2.70 (2.14, 3.42) 2.01 (1.56, 2.60) 
Overall p-value, p-trend   <0.001, <0.001 <0.001, <0.001   <0.001, <0.001 0.003, <0.001   <0.001, <0.001 <0.001, <0.001 
Sex             
Men 422 54.3 1.00 1.00  77.5 1.00 1.00  11.2 1.00 1.00 
Women 364 61.8 1.36 (1.03, 1.81) 1.18 (0.85, 1.63)  82.1 1.34 (0.94, 1.90) 1.22 (0.81, 1.85)  8.8 1.25 (1.07, 1.45) 1.22 (1.04, 1.42) 
p-value   0.03 0.33   0.11 0.34   0.004 0.012 
ECOG performance status             
Fully active 260 37.3 1.00 1.00  65.9 1.00 1.00  15.2 1.00 1.00 
Not fully active 420 68.8 3.71 (2.68, 5.13) 2.53 (1.76, 3.64)  88.1 4.19 (2.84, 6.18) 2.90 (1.87, 4.51)  7.2 2.13 (1.79, 2.53) 1.74 (1.45, 2.08) 
p-value   < 0.0001 < 0.001   < 0.001 < 0.001   < 0.001 < 0.001 
Charlson comorbidity index (score)            
Low (0) 340 49.1 1.00 1.00  74.1 1.00 1.00  12.4 1.00 1.00 
Medium (1) 243 57.6 1.40 (1.01, 1.96) 1.12 (0.77, 1.63)  80.3 1.42 (0.95, 2.11) 1.10 (0.70, 1.73)  9.9 1.20 (1.00, 1.43) 1.04 (0.86, 1.25) 
High (≥ 2) 199 72.9 2.78 (1.91, 4.06) 2.50 (1.64, 3.81)  88.9 2.81 (1.70, 4.66) 2.22 (1.26, 3.91)  8.0 1.62 (1.34, 1.95) 1.43 (1.18, 1.74) 
Overall p-value, p-trend   <0.001,<0.001 <0.001, <0.001   <0.001,<0.001 0.02, 0.010   <0.001,<0.001 <0.001, 0.001 
Place of residence             
Major city 547 56.5 1.00 1.00  77.9 1.00 1.00  10.4 1.00 1.00 
Inner Regional 163 58.9 1.10 (0.77, 1.58) 1.19 (0.80, 1.79)  81.6 1.26 (0.81, 1.96) 1.54 (0.92, 2.59)  10.1 1.11 (0.93, 1.34) 1.17 (0.97, 1.42) 
Outer regional/remote 76 64.5 1.40 (0.85, 2.31) 1.56 (0.88, 2.77)  88.2 2.11 (1.02, 4.36) 3.10 (1.34, 7.20)  8.4 1.29 (1.00, 1.66) 1.33 (1.03, 1.72) 
Overall p-value, p-trend   0.40, 0.19 0.27, 0.11   0.096, 0.03 0.01, 0.003   0.11, 0.036 0.04, 0.01 
Socio-economic Status of area of residence - quintiles          
Most disadvantaged 156 63.5 1.00 1.00  82.0 1.00 1.00  8.8 1.00 1.00 
Second 171 57.3 0.77 (0.50, 1.21) 0.91 (0.55, 1.50)  77.8 0.77 (0.44, 1.32) 0.91 (0.49, 1.68)  10.1 0.87 (0.69, 1.10) 1.03 (0.81, 1.31) 
Third 158 54.4 0.69 (0.44, 1.08) 0.68 (0.41, 1.14)  78.5 0.80 (0.46, 1.39) 0.81 (0.43, 1.52)  10.8 0.85 (0.67, 1.08) 0.81 (0.63, 1.04) 
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   1-year mortalitya  2-year mortalitya  Overall survivalb 
Exposure variable 
Nc 
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI) 
 % 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI) 
 Median 
(months) 
Crude HR 
(95% CI) 
Adjusted HRd 
(95% CI) 
Fourth 160 56.9 0.76 (0.48, 1.19) 0.91 (0.54, 1.51)  78.1 0.78 (0.45, 1.36) 0.95 (0.51, 1.78)  10.3 0.90 (0.71, 1.14) 1.05 (0.83, 1.34) 
Least disadvantaged 136 56.6 0.75 (0.47, 1.20) 0.80 (0.47, 1.35)  82.4 1.02 (0.56, 1.86) 1.05 (0.54, 2.05)  10.4 0.93 (0.73, 1.19) 1.01 (0.79, 1.31) 
Overall p-value, p-trend   0.57, 0.26 0.64, 0.46   0.76, 0.97 0.94, 0.86   0.70, 0.71 0.22, 0.86 
Tumour site             
Head/neck/uncinate process 647 58.4 1.00 1.00  81.1 1.00 1.00  10.1 1.00 1.00 
Body 40 67.5 1.48 (0.75, 2.92) 1.71 (0.81, 3.62)  87.5 1.63 (0.62, 4.24) 1.92 (0.68, 5.42)  8.8 1.20 (0.87, 1.67) 1.40 (1.00, 1.96) 
Tail 43 41.9 0.51 (0.27, 0.96) 0.63 (0.32, 1.24)  58.1 0.32 (0.17, 0.61) 0.36 (0.18, 0.72)  18.3 0.53 (0.36, 0.77) 0.60 (0.41, 0.88) 
Multiple/other 33 51.5 0.76 (0.38, 1.52) 0.77 (0.35, 1.68)  81.8 1.05 (0.42, 2.59) 1.13 (0.41, 3.10)  11.7 0.93 (0.63, 1.35) 1.10 (0.75, 1.62) 
Overall p-value   0.091 0.22   0.003 0.02   0.005 0.008 
Clinical Stage             
Confined to pancreas 225 45.8 1.00 1.00  68.0 1.00 1.00  13.4 1.00 1.00 
Locally advanced 561 62.6 1.98 (1.45, 2.71) 2.13 (1.48, 3.06)  84.3 2.53 (1.76, 3.63) 2.55 (1.68, 3.87)  9.3 1.59 (1.34, 1.89) 1.54 (1.29, 1.83) 
Overall p-value   <0.001 <0.001   < 0.001 <0.001   <0.001 < 0.001 
Health Service Factors             
Evidence of MDT review             
No/ Not stated 518 61.8 1.00 1.00e  81.9 1.00 1.00e  9.3 1.00 1.00e 
Yes 268 50.0 0.62 (0.46, 0.83) 0.80 (0.56, 1.14)  75.4 0.68 (0.48, 0.97) 0.77 (0.50, 1.18)  11.9 0.76 (0.65, 0.89) 0.88 (0.74, 1.04) 
Overall P value   0.002 0.22   0.033 0.22   0.001 0.14 
First facility volume (number of patients)           
30 + 411 52.1 1.00 1.00e  76.2 1.00 1.00e  11.4 1.00 1.00e 
10 - 29 232 60.3 1.40 (1.01, 1.94) 1.17 (0.79, 1.72)  81.0 1.34 (0.90, 1.99) 0.93 (0.58, 1.49)  9.3 1.20 (1.01, 1.43) 1.03 (0.86, 1.24) 
< 10 132 74.2 2.65 (1.72, 4.10) 1.84 (1.07, 3.16)  90.2 2.87 (1.55, 5.31) 2.04 (0.91, 4.58)  7.2 1.71 (1.39, 2.09) 1.21 (0.95, 1.53) 
Overall P value, P trend   0.043, <0.001 0.09, 0.04   0.003, 0.001 0.17, 0.23   <0.001, <0.001 0.29, 0.17 
First specialist seen             
Hepatobiliary surgeon 145 50.3 1.00 1.00e  73.1 1.00 1.00e  12.0 1.00 1.00e 
Gastroenterologist 235 54.5 1.18 (0.78, 1.79) 0.83 (0.51, 1.34)  78.7 1.36 (0.84, 2.20) 0.96 (0.55, 1.67)  11.2 1.23 (0.98, 1.55) 1.02 (0.80, 1.29) 
General Surgeon 292 61.0 1.54 (1.03, 2.30) 0.87 (0.54, 1.40)  82.2 1.70 (1.06, 2.73) 1.04 (0.59, 1.82)  9.0 1.40 (1.13, 1.75) 0.99 (0.78, 1.26) 
Other specialty 114 65.8 1.90 (1.14, 3.14) 0.90 (0.49, 1.65)  83.3 1.84 (1.00, 3.40) 0.91 (0.42, 1.94)  2.4 1.56 (1.20, 2.04) 0.92 (0.68, 1.23) 
Overall P value   0.037 0.89   0.11 0.98   0.004 0.87 
Seen by hepato-biliary surgeon            
         No / Not stated 395 65.6 1.00 1.00e  87.1 1.00 1.00e  8.0 1.00 1.00e 
         Yes 391 49.9 0.52 (0.39, 0.70) 0.91 (0.64, 1.29)  72.1 0.38 (0.27, 0.55) 0.58 (0.37, 0.90)  12.1 0.61 (0.52, 0.70)  .81 (0.69, 0.96) 
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   1-year mortalitya  2-year mortalitya  Overall survivalb 
Exposure variable 
Nc 
% 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI) 
 % 
dead 
Crude OR 
(95% CI) 
Adjusted ORd 
(95% CI) 
 Median 
(months) 
Crude HR 
(95% CI) 
Adjusted HRd 
(95% CI) 
Overall P value   < 0.001 0.58   < 0.001 0.015   < 0.001 0.013 
Received chemotherapy             
No / Not stated 387 74.4 1.00 1.00e  88.1 1.00 1.00e  5.5 1.00 1.00e 
Yes 399 41.6 0.24 (0.18, 0.33) 0.34 (0.23, 0.50)  71.4 0.34 (0.23, 0.49) 0.50 (0.31, 0.82)  14.1 0.57 (0.48, 0.66) 0.58 (0.48, 0.70) 
Overall P value   < 0.001 < 0.001   < 0.001 0.005   < 0.001 < 0.001 
Resection             
        No resection attempted 421 74.8 1.00 1.00e  92.4 1.00 1.00e  6.8 1.00 1.00e 
        Resection attempted 365 38.1 0.21 (0.15, 0.28) 0.39 (0.26, 0.57)  64.9 0.15 (0.10, 0.23) 0.30 (0.18, 0.52)  15.1 0.37 (0.32, 0.43) 0.56 (0.46, 0.68) 
        Overall P value   < 0.001 < 0.001   < 0.001 < 0.001   < 0.001 < 0.001 
a Crude and adjusted odds ratios (ORs) estimated using logistic regression. P values are from Type 3 tests of effects using Wald’s chi-square statistic. Overall P values are for 
test of association. 
b Median survival estimated using Kaplan-Meier methods. Crude and adjusted hazards ratios (HRs) estimated using Cox proportional hazards (PH) and stratified Cox models, 
respectively. P values are from Type 3 tests of effects using Wald’s chi-square statistic. Overall P values are for test of association. 
cMissing data: Socio-economic status, n= 5;  Performance status,  n = 106; comorbidities, n = 4; First facility volume , n = 11. 
dAdjusted for patient (age, performance status (ECOG), place of residence(ARIA), Charlson comorbidity index) and tumour (clinical stage, site of tumour) factors. SES not 
adjusted for place of residence.  
eAdjusted for patient and tumour factors and receipt of chemotherapy 
Place of residence groups defined by Accessibility/Remoteness Index of Australia; ECOG, Eastern Cooperative Oncology Group; SES Socio-Economic Status defined by 
Socio-Economic Indexes for Areas; First facility volume by number of study participant initial presentations. 
MDT= multi-disciplinary team 
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Compared with patients from major cities, risk of dying within two years was greater for 
patients from inner regional areas (AOR 1.54; 95% confidence interval [CI]: 0.92 - 2.59) and 
outer regional/ remote areas (AOR 3.10; 95% CI: 1.34 – 7.20). Increasing remoteness was 
associated with poorer survival (p trend = 0.01). Compared with those from major cities, those 
from outer regional/remote areas were 33% more likely to die (AHR 1.33, 95% CI: 1.03 – 
1.72). This difference in survival remained after adjusting for attempted surgery (p trend = 
0.01, AHR 1.31, 95% CI: 1.01 – 1.70). There were no associations between socio-economic 
status and mortality or survival in multivariable analyses. After adjusting for patient and 
tumour factors women had worse overall survival than men (AHR 1.22; 95% CI: 1.04 - 1.42), 
but when also adjusted for attempted surgery the difference was reduced and no longer 
statistically significant (AHR 1.15; 95% CI 0.99 – 1.35, p = 0.07). 
Each health-service factor was associated with survival and mortality. Patients reviewed by an 
MDT had lower odds of dying up to one or two years after diagnosis and higher overall 
survival, but after adjustment for patient and tumour characteristics, the estimates were no 
longer statistically significant (Table 1). Being seen by a hepatobiliary surgeon was associated 
with improved overall survival (AHR 0.80; 95% CI: 0.69 – 0.96).  Compared with patients 
who were first admitted to a facility that managed at least 30 pancreatic cancer patients 
annually, those first admitted to a hospital that treated fewer than 10 had higher one-year 
mortality (AOR 1.84; 95% CI: 1.07 – 3.16). Estimated survival and mortality rates were more 
favourable for patients who had an attempted resection (AHR 0.56; 95% CI: 0.46 - 0.68). 
Patients who received chemotherapy were less likely to die up to a year after diagnosis 
compared to those who had no record of chemotherapy treatment (AOR 0.34; 95% CI 0.23 – 
0.50).  
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Determinants of attempted resection in all patients with non-metastatic disease 
Older age, poorer performance status, and/or higher comorbidity scores were each significantly 
inversely associated with the likelihood of having resection attempted (Table 2 and 
supplementary table 1). 
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Table 2. Associations between adjusted patient, tumour and health-service factors and (1) attempted resection for patients with non-metastatic diseasea (n = 786 ) ; (2) classification of disease 
resectabilitya for patients with locally advanced diseasea  (n = 561), and(3) attempted resection for patients classified as resectablea (n = 510).  
 
  (1) All Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectable 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Adjusted ORb  (95% CI)  Total n (%) Adjusted ORb  (95% CI)  Total n (%) Adjusted ORb (95% CI) 
Patient / tumour factors            
Age at diagnosis, years            
< 60 141 103 (73) 1.00c  98 62 (63) 1.00c  105  103 (98) 1.00c 
60 - 69 218 135 (62) 0.59 (0.37, 0.94)  163 91 (56) 0.71 (0.42, 1.20)  146  135 (92) 0.22 (0.05, 1.04) 
70 - 79 223 107 (48) 0.33 (0.21, 0.53)  161 76 (47) 0.51 (0.30, 0.85)  138  107 (78) 0.06 (0.01, 0.27) 
         ≥ 80 204 20 (10) 0.04 (0.02, 0.07)  139 56 (40) 0.38 (0.22. 0.66)  121  20 (17) 0.00 (0.00, 0.02) 
 Overall p value, p trend   < 0.001, < 0.001    0.002, < 0.001    < 0.001, < 0.001 
Sex            
Men 422 222 (53) 1.00d  299 164 (55) 1.00d  287  222 (77) 1.00d 
Women 364 143 (39) 0.77 (0.55, 1.08)  262 121 (46) 0.74 (0.52, 1.05)  223  143 (64) 0.89 (0.48, 1.65) 
 Overall p value   0.13    0.09    0.71 
Performance status            
Fully active  260  183 (70) 1.00e  160 95 (59) 1.00e  195  183 (94) 1.00e 
Not fully active  420 134 (32) 0.24 (0.17, 0.35)  325 156 (48) 0.71 (0.47, 1.05)  251  134 (53) 0.06 (0.02, 0.14) 
Overall p value   < 0.001    0.09    < 0.001 
Charlson comorbidity index (score)           
Low (0) 340 184 (54) 1.00e  252 126 (50) 1.00e  214  184 (86) 1.00e 
Medium (1) 243 105 (43) 0.78 (0.54, 1.14)  177 91 (51) 1.15 (0.78, 1.71)  157   105 (67) 0.40 (0.20, 0.80) 
High (≥ 2) 199 74 (37) 0.59 (0.39, 0.88)  130 66 (51) 1.10 (0.72, 1.70)  135  74 (55) 0.15 (0.07, 0.31) 
Overall p value, p trend   0.03, 0.01    0.76, 0.59    < 0.001, < 0.001 
Place of residence            
Major city 542 258 (48) 1.00d  386 206 (53) 1.00d  362  258 (71) 1.00d 
Inner Regional 163 74 (45) 0.84 (0.55, 1.28)  119 50 (50) 0.90 (0.59, 1.38)  104  74 (71) 0.68 (0.32, 1.46) 
Outer regional / remote 76 31 (41) 0.61 (0.33, 1.10)  53 19 (36) 0.48 (0.26, 0.89)    42  31 (74) 0.44 (0.13, 1.50) 
Overall p value, p trend   0.22, 0.09    0.07, 0.04    0.31, 0.13 
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  (1) All Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectable 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Adjusted ORb  (95% CI)  Total n (%) Adjusted ORb  (95% CI)  Total n (%) Adjusted ORb (95% CI) 
SES - quintiles              
Most disadvantaged 156 73 (47) 1.00d  110 55 (50) 1.00d  101  73 (72) 1.00d 
Second 171 80 (48) 0.77 (0.46, 1.31)  123 65 (53) 1.01 (0.60, 1.72)  113  80 (71) 0.51 (0.19, 1.32) 
Third 158 68 (43) 0.78 (0.46, 1.34)  113 50 (44) 0.72 (0.42, 1.24)    95  68 (72) 0.95 (0.34, 2.65) 
Fourth 160 77 (48) 0.85 (0.50, 1.45)  107 56 (52) 0.95 (0.55, 1.65)  109  77 (71) 0.56 (0.21, 1.50) 
Least disadvantaged 136 65 (48) 0.93 (0.53, 1.64)  105 59 (56) 1.19 (0.68, 2.07)    90  65 (72) 1.56 (0.55, 4.46) 
  Overall p value, p trend   0.86, 1.00    0.50, 0.69    0.18, 0.43 
Tumour site            
Head/neck/uncinate process 647 298 (46) 1.00d  463 240 (52) 1.00d  424  298 (70) 1.00d 
Body 40 14 (35) 0.46 (0.21, 0.99)  29 8 (28) 0.33 (0.14, 0.77)    19    14 (74) 0.98 (0.19, 4.99) 
Tail 43 33 (77) 3.62 (1.58, 8.33)  27 21 (78) 3.09 (1.20, 7.94)    37    32 (89)     3.39 (0.85, 13.57) 
Multiple/other 33 13 (39) 0.55 (0.24, 1.24)  25 8 (32) 0.45 (0.18, 1.10)    16    13 (81) 1.25 (0.19, 8.13) 
  Overall p value   0.001    0.001    0.39 
Health Service Factors            
Evidence of MDT review            
No / not stated 518 239 (46) 1.00f  355 193 (54) 1.00f  356  239 (67) 1.00f 
Yes 268 126 (47) 0.60 (0.42, 0.86)  206   92 (45) 0.33 (0.14, 0.78)  154  126 (82) 1.09 (0.54, 2.21) 
Overall p value   0.01    0.01    0.81 
First facility volumeg            
 30 +  411 226 (55) 1.00f  275 153 (56) 1.00f  289  226 (78) 1.00f 
10 – 29 232 97 (42) 0.70 (0.47, 1.05)  170   84 (49) 0.92 (0.61, 1.38)  146    97 (66) 0.52 (0.20, 1.537) 
< 10 132 42 (32) 0.57 (0.34, 0.97)  107   48 (45) 0.88 (0.53, 1.45)    73    42 (58) 0.51 (0.15, 1.67) 
Overall p value, p trend   0.06, 0.02    0.85, 0.58    0.34, 0.19 
Specialist first seen            
         Hepatobiliary surgeon 235 87 (60) 1.00f  87 44 (51) 1.00f  102    87 (85) 1.00f 
Gastroenterologist 235 123 (52) 0.99 (0.61, 1.61)  173 97 (56) 1.42 (0.83, 2.43)  159  123 (66) 0.75 (0.29, 1.94) 
General Surgeon 292 118 (40) 0.70 (0.43, 1.13)  222 108 (49) 1.11 (0.66, 1.89)  178  118 (66) 0.64 (0.25, 1.63) 
Other 114 37 (32) 0.67 (0.36, 1.25)  79 36 (46) 1.08 (0.56, 2.08)    71    37 (52) 0.58 (0.19, 1.79) 
  Overall p value   0.24    0.52    0.77 
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  (1) All Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectable 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Adjusted ORb  (95% CI)  Total n (%) Adjusted ORb  (95% CI)  Total n (%) Adjusted ORb (95% CI) 
Seen by hepato-biliary surgeon            
No / not stated 395 106 (27) 1.00f  308 129 (42) 1.00f  216 106 (49) 1.00f 
Yes 391 259 (66) 3.77 (2.63, 5.39)  253 156 (62) 1.95 (1.35, 2.82)  294 259 (88) 6.78 (3.38, 13.59) 
Overall p value   < 0.001    < 0.001    < 0.001 
Pancreas protocol computerised tomography            
No / not stated 406 173 (43) 1.00f  294 150 (51) 1.00f  262 173 (66) 1.00f 
Yes 380 192 (51) 0.96 (0.68, 1.35)  267 135 (51) 0.97 (0.61, 1.23)  248 192 (77) 1.33 (0.71, 2.50) 
Overall p value   0.82    0.42    0.37 
Plain computerised tomography            
No / not stated 261 133 (51) 1.00f  189 104 (55) 1.00f  176 133 (76) 1.00f 
Yes 525 232 (44) 0.76 (0.54, 1.12)  372 181 (49) 0.79 (0.55, 1.15)  334 232 (69) 0.40 (0.19, 0.83) 
Overall p value   0.17    0.22    0.01 
Endoscopic ultrasound            
No / not stated 434 186 (43) 1.00f  311 168 (54) 1.00f  291 186 (64) 1.00f 
Yes 352 179 (51) 0.85 (0.60, 1.20)  250 117 (47) 0.60 (0.41, 0.86)  219 179 (82) 1.12 (0.59, 2.10) 
Overall p value   0.35    0.006    0.74 
Laparoscopy            
No / not stated 648 252 (39) 1.00f  455 201 (44) 1.00f  394 252 (64) 1.00f 
Yes 138 113 (82) 4.84 (2.92, 8.02)  106 84 (79) 4.70 (2.77, 7.98)  116 113 (97) 12.15 (3.40, 43.40) 
Overall p value   < 0.001    < 0.001    < 0.001 
Endoscopic retrograde cholangiopancreatography            
No / not stated 399 190 (48) 1.00f  276 134 (49) 1.00f  257 190 (74) 1.00f 
Yes 387 175 (45) 1.04 (0.74, 1.47)  285 151 (53) 1.26 (0.89, 1.79)  253 175 (69) 0.86 (0.46, 1.63) 
Overall p value   0.81    0.20    0.65 
Magnetic resonance imaging /cholangiopancreatography            
No / not stated 642 285 (44) 1.00f  462 236 (51) 1.00f  416 285 (69) 1.00f 
Yes 144 80 (56) 1.10 (0.72, 1.68)  99 49 (49) 0.81 (0.51, 1.27)  94 80 (85) 1.42 (0.60, 3.35) 
Overall p value   0.67    0.36    0.43 
a Based on clinical staging including imaging or exploratory laparoscopy. 
b Adjusted odds ratios (ORs,) estimated using logistic regression. 
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Adjusted for: c Place of residence (major city, inner regional, outer regional/remote/very remote); d Age at diagnosis (<60, 60-69, 70-79, 80+ years) and performance status (0, 1, 2+, not stated); 
e Age at diagnosis; f Age at diagnosis, performance status and place of residence. 
g Results from a mixed effects model with hospital as random intercept to adjust for hospital clustering. 
Place of residence groups defined by Accessibility/Remoteness Index of Australia (ARIA); Performance status defined by Eastern Cooperative Oncology Group (ECOG); SES Socio-Economic 
Status defined by Socio-Economic Indexes for Areas; First facility volume by the number of study participant initial presentations.  
Missing data: SES, n = 5; Place of residence, n = 5; Tumour site, n = 23; ECOG, n = 106; Charlson comorbidity index, n = 4; First inpatient facility volume, n = 11. 
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Patients from more remote areas had lower odds of attempted surgery compared with those 
living in major cities (AOR 0.61; 95% CI: 0.33 –1.10), although this was not statistically 
significant. Having tumour only in the tail of the pancreas was associated with a greater 
likelihood of attempted resection compared to having tumour in the head, neck or uncinate 
process (AOR 3.62; 95% CI: 1.58 – 0.33). Presentation at a MDT meeting and low volume of 
the facility where the patient was first admitted were associated with lower odds of having an 
attempted resection (AORs 0.60; 95% CI: 0.42 - 0.86, and 0.57; 95% CI: 0.34 - 0.97) 
respectively). If the patient was seen by a hepatobiliary surgeon or had a staging laparoscopy 
they were more likely to have surgery (AORs 3.77; 95% CI: 2.63 – 5.39 and 4.84; 95% CI: 
2.92 – 8.02 respectively). 
Determinants of classification of cancer as resectable in patients with locally advanced 
disease  
Factors associated with having a tumour classified as potentially resectable amongst patients 
with locally advanced disease were younger age (< 60 versus ≥ 70 years: 63% versus 44%, p 
< 0.01), better ECOG performance status (fully active versus not fully active: 59% versus 48%, 
p = 0.02) and living in a major city (major city vs remote / outer regional: 53% versus 36%, p 
= 0.02) (Table 2).  After adjustment for patient factors, the association with place of residence 
remained statistically significant (AOR 0.48; 95% CI: 0.26 –0.89) but further adjustment for 
health-service factors attenuated the association and it was no longer statistically significant 
(AOR 0.78; 95% CI: 0.38 – 1.59). Age remained associated with classification of resectability 
even after controlling for patient, tumour and health-service factors. 
Patients presented at a MDT meeting were less likely to be assessed as having a potentially 
resectable tumour than those with no evidence of being reviewed by a MDT (AOR 0.33; 95% 
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CI: 0.14 - 0.78). If patients were seen by a hepatobiliary surgeon they had almost twice the 
odds of being classified as having resectable disease (AOR 1.95; 95% CI 1.35- 2.82). Patients 
who underwent an EUS compared with those who did not were less likely to be classified as 
having potentially resectable disease (AOR 0.60; 95% CI: 0.41 – 0.86), whereas the opposite 
was observed if they had a laparoscopy (AOR 4.70; 95% CI: 2.77 – 7.98). 
Determinants of attempted surgery in patients classified as having potentially resectable 
disease 
Amongst those patients classified as potentially resectable we found that 28% (n = 145) did not 
proceed to surgery. The recorded reasons were predominantly comorbidities and/or age (88%, 
n = 127) with only 12% (n = 18) recorded as other or not stated. There were statistically 
significant associations between age, performance status and comorbidities and whether 
surgery was attempted (Table 2). 
There was no difference in the proportion of patients who proceeded to attempted resection 
according to location of residence. After adjustment for age and performance status people 
living in more remote regions had non-significant lower odds compared to patients living in 
major cities. Most health system factors and investigations were significantly associated with 
attempted resection, but after adjusting for patient factors, only being seen by a hepatobiliary 
surgeon (AOR 6.78; 95% CI: 3.38 – 13.59) and having a laparoscopy (AOR 12.15; 95% CI: 
3.40 – 43.40) were positively associated with attempted resection.  
Associations between age, location of residence and health system factors 
Age and place of residence were not significantly associated with each other, but both were 
associated with being assessed by a hepatobiliary surgeon, the specialist first seen and the 
facility volume where the patient was first an inpatient (Supplementary table 2). Patients living 
in more remote regions were less likely to undergo EUS and ERCP than those living in major 
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cities, and older patients were less likely to undergo pancreas-protocol CT and MRI or MRCP, 
EUS or have laparoscopies as part of their clinical staging investigations.  The likelihood of 
laparoscopy (8% versus 22%, p = 0.001) and EUS (33% versus 53%, p<0.001) was also lower 
for patients initially admitted to a low rather than high volume facility.  
DISCUSSION 
In this population-based cohort of patients with non-metastatic pancreatic cancer we found, as 
expected, that those with more advanced disease and those who were older, who had poorer 
performance status or more comorbidities were more likely to die within one or two years and 
had poorer overall survival. Lower survival was observed for people who lived in regional or 
remote areas compared with those living in capital cities, even after adjusting for differences 
in patient and tumour factors.  
The percentage of patients with non-metastatic disease alive at one year (42%) in our cohort 
was considerably higher than the ~30% reported in some previous population-based studies18, 
25, 26 but similar to estimates from studies using more recent registry data.27, 28 Our findings that 
clinical disease stage, performance status, presence of comorbidities and age influence survival 
are consistent with international and national reports.3, 4, 8, 29  
The proportion of our cohort classified as having potentially resectable disease was higher than 
that in previous international studies (65% versus 37% - 45%)16, 28 with some studies 
suggesting that age, sex, medical insurance and site of the tumour are associated with 
resectability.16, 30 Almost three-quarters of those identified as resectable proceeded to an 
attempted resection which is considerably higher than the ~20-60% in earlier reports.16, 18, 28, 31 
The higher likelihood of being classified as having resectable disease and  higher rates of 
attempted resection in this study may be due to temporal changes in the definition of 
resectability as surgical techniques have improved.32   
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The association between place of residence and survival has been observed in other settings3 
with travelling distance to receive treatment33 and the lack of high-volume specialist centres in 
more rural areas34 being suggested as reasons for this. Our results suggest that the poorer 
survival of patients living in regional and remote areas may be at least partially due to them 
being less likely to be classified as having resectable disease. Although they are equally likely 
to undergo surgery once classified as resectable, this results in a lower overall proportion 
undergoing surgery. While patients living in lower socio-economic areas or more distant from 
health services may choose not to undergo treatment, it is important that adequate staging to 
determine resectability is undertaken in order that they can make an informed decision about 
their treatment pathways. 
We found that only half of the patients were reviewed by a hepatobiliary surgeon at any time 
during their disease course, and the proportion was significantly higher in metropolitan areas 
than in regional and remote areas and in younger than in older patients. Similarly, older patients 
and those living in remote areas were less likely to be first admitted to a high volume hospital. 
These results are inconsistent with guidelines12, 13, 35 and the views of clinical experts36 which 
recommend that all patients diagnosed with non-metastatic disease should be reviewed by an 
experienced hepatobiliary surgeon, ideally supported by a multidisciplinary team. A recent 
study reported that patients with non-metastatic pancreatic cancer had a greater likelihood of 
having surgical treatment when clinical staging was established in a specialised pancreatic 
cancer centre.37 EUS is used to assess the tumour, vascular invasion, tissue diagnosis, lymph 
node disease, small volume liver disease and peritoneal ascites, all of which help to ascertain 
the resectability of the tumour. This may explain why patients who had this investigation were 
less likely to be classified as resectable. Laparoscopy, which is used selectively in most 
specialised units, tends to be used in patients thought to be resectable to detect potential small-
volume peritoneal disease, so patients were more likely to proceed to surgery following this 
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investigation. We also demonstrated that being seen by a hepatobiliary surgeon was associated 
with a greater likelihood of being diagnosed with resectable disease. While this may be due to 
reverse causality, being seen by a hepatobiliary surgeon appears to mediate the association 
between location of residence and classification of tumour resectability, suggesting that 
improving access to specialist care may increase the proportion of patients living in non-
metropolitan areas who undergo surgery.   
Review by a MDT is the standard of care for patients without metastatic disease12 and has been 
shown to improve survival.38, 39 We found that review by an MDT was associated with a lower 
likelihood of being classified as having resectable disease, most likely because clinicians 
tended to present patients with borderline resectable disease to the MDT. Despite this, after 
adjustment for patient factors, MDT review was associated with improved overall survival, 
both for patients who did and did not undergo surgery (data not shown), suggesting that MDT 
management is an indicator of improved overall care.  A follow-up study focussed specifically 
on multi-disciplinary care is needed to determine which patients are presented to MDTs and to 
understand the consequences of not being presented to a specialist MDT in a high-volume 
hospital. 
Given the challenges of pancreatic cancer surgery and its subsequent survival even after 
potentially curative resection, it is appropriate that consideration of quality-of-life and other 
patient factors influence the decision to proceed to recommending resection. In keeping with 
this, we found that age, poor performance status or the presence of comorbidities were given 
as the reason for surgery not to proceed in patients with potentially resectable disease. Our 
results may, however, indicate that in some cases older patients may be considered to have 
non-resectable disease by default and without adequate staging or review by an expert team. In 
the absence of poor performance status or significant comorbidities age is not necessarily a 
contraindication to surgery40 and may indicate a nihilistic attitude amongst some clinicians.41 
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This emphasises the importance of a full staging work up so that patients can make informed 
decisions about their treatment, irrespective of their age. 
Major strengths of our study include the large population-based sample and the comprehensive 
data collected. However, our classification of clinical disease stage as confined to the pancreas, 
locally advanced or metastatic disease, did not allow for the separate classification of 
borderline resectable disease. Pancreatic cancers are categorised on a continuum from 
resectable to unresectable according to involvement of adjacent structures and the presence of 
distant metastases32, 42 but this categorization was performed by numerous surgeons in this 
study and may not be consistent. International more robust criteria for defining resectable 
disease were introduced after the study period.12, 43 It is also possible that at least some of the 
associations with hospital volume, laparaoscopy and hepatobiliary surgeon review arose due 
to reverse-causality.  
In conclusion this study found disparities in survival dependent on where patients live and 
where and by whom they are managed. Initial accurate clinical staging is a critical element in 
the provision of optimal management, with access to hepatobiliary surgeons, high volume 
specialist facilities and multidisciplinary teams shown to be important. Many patients do not 
meet the guidelines that recommend an early review by a hepatobiliary surgeon and by a MDT, 
with access to these services partly dependent on where patients live. Designing health services 
and referral patterns that ensure all patients receive appropriate staging and expert assessment, 
regardless of where and how they enter the health system, has the potential to lead to 
improvements in survival. 
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Supplementary Table 1. Unadjusted associations between patient, tumour and health-service factors and (1) attempted resection for patients with non-metastatic diseasea  (n =  786);   
                                       (2) classification of disease resectabilitya for patients with locally advanced diseasea  (n = 561); (3) attempted resection for patients classified as resectablea (n = 510).  
 
  (1) Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectablea 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb (95% CI) 
Patient / tumour factors            
Age at diagnosis, years            
< 60 141 103 (73) 1.00  98 62 (63) 1.00  105  103 (98) 1.00 
60 - 69 218 135 (62) 0.60 (0.38, 0.95)  163 91 (56) 0.73 (0.44, 1.23)  146  135 (92) 0.24 (0.05, 1.10) 
70 - 79 223 107 (48) 0.34 (0.22, 0.54)  161 76 (47) 0.52 (0.31, 0.87)  138  107 (78) 0.07 (0.02, 0.29) 
         ≥ 80 204 20 (10) 0.04 (0.02, 0.07)  139 56 (40) 0.39 (0.23, 0.67)  121  20 (17) 0.00 (0.00, 0.02) 
 Overall p value, p trend   <0.001, <0.001    0.002, < 0.001    <0.001, <0.001 
Sex            
Men 422 222 (53) 1.00  299 164 (55) 1.00  287  222 (77) 1.00 
Women 364 143 (39) 0.58 (0.44, 0.77)  262 121 (46) 0.71 (0.51, 0.99)  223  143 (64) 0.52 (0.35, 0.77) 
 Overall p value   <0.001    0.04    0.001 
Performance status            
Fully active  260  183 (70) 1.00  160 95 (59) 1.00  195  183 (94) 1.00 
Not fully active  420 134 (32) 0.20 (0.14, 0.28)  325 156 (48) 0.63 (0.43, 0.93)  251  134 (53) 0.08 (0.04, 0.14) 
Overall p value   <0.001    0.02    < 0.001 
Charlson comorbidity index (score)            
Low (0) 340 184 (54) 1.00  252 126 (50) 1.00  214  184 (86) 1.00 
Medium (1) 243 105 (43) 0.65 (0.46, 0.90)  177 91 (51) 1.06 (0.72, 1.55)  157   105 (67) 0.34 (0.20, 0.56) 
High (≥ 2) 199 74 (37) 0.50 (0.35, 0.72)  130 66 (51) 1.03 (0.68, 1.57)  135  74 (55) 0.20 (0.12, 0.34) 
Overall p value, p trend   < 0.001, < 0.001    0.96, 0.85    < 0.001, < 0.001 
Place of residence            
Major city 542 258 (48) 1.00  386 206 (53) 1.00  362  258 (71) 1.00d 
Inner Regional 163 74 (45) 0.92 (0.64, 1.30)  119 50 (50) 0.89 (0.59, 1.34)  104  74 (71) 0.99 (0.61, 1.61) 
Outer regional / remote 76 31 (41) 0.76 (0.47, 1.23)  53 19 (36) 0.49 (0.27, 0.89)    42  31 (74) 1.14 (0.55, 2.34) 
Overall p value, p trend   0.51, 0.26    0.06, 0.03    0.94, 0.80 
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  (1) Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectablea 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb (95% CI) 
SES - quintiles               
Most disadvantaged 156 73 (47) 1.00  110 55 (50) 1.00  101  73 (72) 1.00 
Second 171 80 (48) 1.00 (0.65, 1.54)  123 65 (53) 1.12 (0.67, 1.88)  113  80 (71) 0.93 (0.51, 1.69) 
Third 158 68 (43) 0.86 (0.55, 1.34)  113 50 (44) 0.79 (0.47, 1.34)    95  68 (72) 0.97 (0.52, 1.80) 
Fourth 160 77 (48) 1.05 (0.68, 1.64)  107 56 (52) 1.10 (0.64, 1.87)  109  77 (71) 0.92 (0.51, 1.68) 
Least disadvantaged 136 65 (48) 1.04 (0.66, 1.65)  105 59 (56) 1.28 (0.75, 2.19)    90  65 (72) 1.00 (0.53, 1.88) 
  Overall p value, p trend   0.90, 0.81    0.48, 0.46    1.00, 0.98 
Tumour site            
Head/neck/uncinate process 647 298 (46) 1.00  463 240 (52) 1.00  424  298 (70) 1.00 
Body 40 14 (35) 0.63 (0.32, 1.23)  29 8 (28) 0.35 (0.15, 0.82)    19    14 (74) 1.18 (0.42, 3.36) 
Tail 43 33 (77) 3.86 (1.87, 7.97)  27 21 (78) 3.25 (1.29, 8.20)    37    32 (89)     3.49 (1.21, 10.05) 
Multiple/other 33 13 (39) 0.76 (0.37, 1.56)  25 8 (32) 0.44 (0.19, 1.03)    16    13 (81) 1.83 (0.51, 6.54) 
  Overall p value   < 0.001    0.001    0.11 
Health Service Factors            
Evidence of MDT review            
No / not stated 518 239 (46) 1.00  355 193 (54) 1.00  356  239 (67) 1.00 
Yes 268 126 (47) 1.04 (0.77, 1.39)  206   92 (45) 0.68 (0.48, 0.96)  154  126 (82) 2.20 (1.38, 3.51) 
Overall p value   0.82    0.03    0.001 
First facility volumeg            
 30 + 411 226 (55) 1.00  275 153 (56) 1.00  289  226 (78) 1.00 
10 – 29 232 97 (42) 0.59 (0.42, 0.81)  170   84 (49) 0.78 (0.53, 1.14)  146    97 (66) 0.55 (0.35, 0.86) 
< 10 132 42 (32) 0.38 (0.25, 0.58)  107   48 (45) 0.65 (0.41, 1.02)    73    42 (58) 0.38 (0.22, 0.65) 
Overall p value, p trend   < 0.001, < 0.001    0.13, 0.05    < 0.001, < 0.001 
Specialist first seen            
         Hepatobiliary surgeon 235 87 (60) 1.00  87 44 (51) 1.00  102    87 (85) 1.00 
Gastroenterologist 235 123 (52) 0.73 (0.48, 1.11)  173 97 (56) 1.25 (0.74, 2.09)  159  123 (66) 0.59 (0.30, 1.14) 
General Surgeon 292 118 (40) 0.45 (0.30, 0.68)  222 108 (49) 0.93 (0.56, 1.52)  178  118 (66) 0.34 (0.18, 0.64) 
Other 114 37 (32) 0.32 (0.19, 0.54)  79 36 (46) 0.82 (0.44, 1.51)    71    37 (52) 0.19 (0.09, 0.39) 
  Overall p value   < 0.001    0.36    < 0.001 
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  (1) Non-metastatic disease  (2) Locally advanced diseasea  (3) Classified as resectablea 
  Attempted resection   Classified as resectable   Attempted resection 
Variable Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb  (95% CI)  Total n (%) Crude ORb (95% CI) 
Seen by hepato-biliary surgeon           
No / not stated 395 106 (27) 1.00  308 129 (42) 1.00  216 106 (49) 1.00 
Yes 391 259 (66) 5.35 (3.94, 7.26)  253 156 (62) 2.23 (1.59, 3.13)  294 259 (88) 7.68 (4.93, 11.95) 
Overall p value   < 0.001    < 0.001    < 0.001 
Pancreas protocol computerised tomography          
No / not stated 406 173 (43) 1.00  294 150 (51) 1.00  262 173 (66) 1.00 
Yes 380 192 (51) 1.38 (1.04, 1.82)  267 135 (51) 0.98 (0.70, 1.37)  248 192 (77) 1.76 (1.19, 2.61) 
Overall p value   0.03    0.91    0.005 
Plain computerised tomography           
No / not stated 261 133 (51) 1.00  189 104 (55) 1.00  176 133 (76) 1.00 
Yes 525 232 (44) 0.76 (0.57, 1.03)  372 181 (49) 0.77 (0.55, 1.10)  334 232 (69) 0.74 (0.49, 1.11) 
Overall p value   0.07    0.15    0.15 
Endoscopic ultrasound          
No / not stated 434 186 (43) 1.00  311 168 (54) 1.00  291 186 (64) 1.00 
Yes 352 179 (51) 1.38 (1.04, 1.83)  250 117 (47) 0.75 (0.54, 1.05)  219 179 (82) 2.53 (1.66, 3.84) 
Overall p value   0.03    0.09    <0.001 
Laparoscopy            
No / not stated 648 252 (39) 1.00  455 201 (44) 1.00  394 252 (64) 1.00 
Yes 138 113 (82) 7.10 (4.48, 11.26)  106 84 (79) 4.82 (2.91, 7.99)  116 113 (97) 21.22 (6.62, 68.03) 
Overall p value   < 0.001    < 0.001    < 0.001 
Endoscopic retrograde cholangiopancreatography          
No / not stated 399 190 (48) 1.00  276 134 (49) 1.00  257 190 (74) 1.00 
Yes 387 175 (45) 0.91 (0.69, 1.20)  285 151 (53) 1.19 (0.86, 1.66)  253 175 (69) 0.79 (0.54, 1.16) 
Overall p value   0.50    0.29    0.23 
Magnetic resonance imaging /cholangiopancreatography          
No / not stated 642 285 (44) 1.00  462 236 (51) 1.00  416 285 (69) 1.00 
Yes 144 80 (56) 1.57 (1.09, 2.25)  99 49 (49) 0.94 (0.61, 1.45)  94 80 (85) 2.63 (1.44, 4.81) 
Overall p value   0.02    0.77    0.002 
a Based on clinical staging including imaging or exploratory laparoscopy. 
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b Crude odds ratios (ORs,) estimated using logistic regression. 
g Results from a mixed effects model with hospital as random intercept to adjust for hospital clustering. 
Place of residence groups defined by Accessibility/Remoteness Index of Australia (ARIA); Performance status defined by Eastern Cooperative Oncology Group (ECOG); SES Socio-Economic 
Status defined by Socio-Economic Indexes for Areas; First facility volume by the number of study participant initial presentations.  
Missing data: SES, n = 5; Place of residence, n = 5; Tumour site, n = 23; Performance status, n = 106; Charlson comorbidity index, n = 4; First inpatient facility volume, n = 11. 
 
Supplementary Table 2: Associations between patient, tumour and health-service factors and (1) place of residence and (2) age, for patients with non-metastatic 
disease on clinical staging. 
  Place of residence, n (%)  (n = 781)  Age in years, n (%) (n = 786) 
Exposure variable Major  city 
(n = 542) 
Inner  
regional 
(n = 163) 
Outer 
regional/ 
remote 
(n = 76) P valueb 
 
< 60 
(n = 141) 
60 – 69 
(n =218) 
70 – 79 
(n = 223) 
≥ 80 
 (n = 204) P valueb 
Patient / Tumour factors           
Age at diagnosis, years    0.44       
< 60 89 (16) 33 (20) 19 (25)   
Not applicable 
 
60 - 69 161 (29) 40 (25) 17 (22)    
70 - 79 158 (29) 45 (28) 20 (26)    
≥ 80 139 (25) 45 (28) 20 (26)    
Sex    0.89      < 0.001 
Men 292 (54) 85 (52) 42 (55)   85 (60) 139 (64) 110 (49) 88 (43)  
Women 85 (46) 78 (48) 34 (45)   56 (40) 79 (36) 113 (51) 116 (57)  
ECOG performance status           
0 173 (32) 56 (34) 27 (36) 0.41  67 (48) 95 (44) 64 (29) 34 (17) < 0.001 
1 159 (29) 57 (35) 24 (32)   52 (37) 73 (33) 73 (33) 42 (21)  
2+ 131 (24) 30 (18) 19 (25)   12 (9) 21 (10) 49 (22) 98 (48)  
Not stated 79 (15) 20 (12) 6 (8)   10 (7) 29 (13) 37 (17) 30 (15)  
Charlson comorbidity index (score)          
Low (0) 244 (45) 63 (39) 30 (40) 0.61  82 (58) 92 (42) 98 (44) 68 (34) 0.002 
Medium (1) 164  (30) 55 (34) 23 (31)   32 (23) 68 (31) 72 (32) 71 (35)  
High (≥ 2) 132 (24) 44 (27) 22 (29)   27 (19) 57 (26) 52 (23) 63 (31)  
Remoteness of residence          0.50 
Major city      89 (63) 157 (73) 157 (71) 139 (68)  
Inner Regional Not applicable   33 (23) 40 (19) 45 (20) 45 (22)  
        Outer regional / remote/ very remote     19 (13) 17 (8) 20 (9) 20 (10)  
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  Place of residence, n (%)  (n = 781)  Age in years, n (%) (n = 786) 
Exposure variable Major  city 
(n = 542) 
Inner  
regional 
(n = 163) 
Outer 
regional/ 
remote 
(n = 76) P valueb 
 
< 60 
(n = 141) 
60 – 69 
(n =218) 
70 – 79 
(n = 223) 
≥ 80 
 (n = 204) P valueb 
SES    < 0.001      0.62 
Most disadvantaged 82 (15) 41 (25) 33 (43)   27 (19) 32 (15) 51 (23) 46 (23)  
Second 84 (16) 72 (44) 15 (20)   34 (24) 44 (21) 50 (23) 43 (21)  
Third 110 (20) 30 (18) 18 (24)   31 (22) 49 (23) 38 (17) 40 (20)  
Fourth 133 (25) 17 (10) 10 (13)   30 (21) 47 (22) 46 (21) 37 (18)  
Least disadvantaged 133 (25) 3 (2) 0   19 (13) 42 (20) 37 (17) 38 (19)  
Tumour site    0.47      0.85 
Head/neck/uncinate 
process 452 (85) 135 (88) 57 (78)   115 (83) 182 (85) 180 (83 ) 170 (87)  
Body 27 (5) 7 (5) 6 (8)   8 (6) 9 (4) 14 (6) 9 (5)  
Tail 31 (6) 5 (3) 7 (10)   9 (7) 12 (6) 15 (7) 7 (4)  
Multiple/other 23 (4) 7 (5) 3 (4)   6 (4) 11 (5) 7 (3) 9 (5)  
Clinical Stage    0.85      0.46 
      Confined to the pancreas 158 (29) 44 (27) 23 (30)   43 (31) 55 (25) 62 (28) 65 (32)  
      Locally advanced disease 389 (71) 119 (73) 53 (70)   98 (69) 163 (75) 161 (72) 139 (68)  
Health System Factors           
Evidence of MDT review    0.13      < 0.001 
No / not stated 351 (65) 105 (64) 58 (76)   71 (50) 133 (61) 149 (67) 165 (81)  
Yes 191 (35) 58 (36) 18 (24)   70 (50) 85 (39) 74 (33) 39 (19)  
Specialist first seen    < 0.001      < 0.001 
Hepatobiliary surgeon 121 (22) 22 (14) 2 (3)   24 (17) 60 (28) 42 (19) 19 (9)  
Gastroenterologist 174 (32) 38 (23) 21 (28)   52 (37) 56 (26) 73 (33) 54 (26)  
General Surgeon 170 (31) 86 (53) 33 (43)   52 (37) 77 (35) 78 (35) 85 (42)  
Other 77 (14) 17 (10) 20 (26)   13 (9) 25 (11) 30 (13) 46 (23)  
First inpatient facility volume    < 0.001      < 0.001 
30 + 339 (63) 58 (36) 13 (17)   84 (60) 127 (58) 117 (52) 83 (41)  
10 – 29 139 (26) 54 (34) 36 (48)   35 (25) 68 (31) 67 (30) 62 (30)  
< 10 56 (10) 49 (30) 26 (35)   19 (13) 21 (10) 36 (16) 56 (27)  
Reviewed by hepato-biliary surgeon   0.009      < 0.001 
No / not stated 262 (48) 80 (49) 51 (67)   54 (38) 86 (39) 101 (45) 154 (75)  
Yes 280 (52) 83 (51) 25 (33)   87 (62) 132 (61) 122 (55) 50 (25)  
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  Place of residence, n (%)  (n = 781)  Age in years, n (%) (n = 786) 
Exposure variable Major  city 
(n = 542) 
Inner  
regional 
(n = 163) 
Outer 
regional/ 
remote 
(n = 76) P valueb 
 
< 60 
(n = 141) 
60 – 69 
(n =218) 
70 – 79 
(n = 223) 
≥ 80 
 (n = 204) P valueb 
Chemotherapy    0.32      < 0.001 
No / not stated 259 (48) 83 (51) 43 (57)   36 (26) 56 (26) 119 (53) 176 (86)  
Yes 283 (52) 80 (49) 33 (43)   105 (74) 162 (74) 104 (47) 28 (14)  
Pancreas protocol computerised tomography  0.20      < 0.001 
No / not stated 269 (50) 93 (57) 42 (55)   59 (42) 101 (46) 118 (53) 128 (63)  
Yes 273 (50) 70 (43) 34 (45)   82 (58) 117 (54) 105 (47) 76 (37)  
Plain computerised tomography   0.01      0.22 
No / not stated 196 (36) 44 (27) 17 (22)   50 (35) 82 (38) 64 (29) 65 (32)  
Yes 346 (64) 119 (73) 59 (78)   91 (65) 136 (62) 159 (71) 139 (68)  
Endoscopic ultrasound    < 0.001      < 0.001 
No / not stated 273 (50) 104 (64) 55 (72)   61 (43) 110 (50) 113 (51) 150 (74)  
Yes 269 (50) 59 (36) 21 (28)   80 (57) 108 (50) 110 (49) 54 (26)  
Laparoscopy    0.11      < 0.001 
No / not stated 439 (81) 135 (83) 69 (91)   107 (76) 174 (80) 168 (75) 199 (98)  
Yes 103 (19) 28 (17) 7 (9)   34 (24) 44 (20) 55 (25) 5 (2)  
Endoscopic retrograde cholangiopancreatography  0.02      0.69 
No / not stated 269 (50) 79 (48) 50 (66)   76 (54) 114 (52) 111 (50) 98 (48)  
Yes 273 (50) 84 (52) 26 (34)   65 (46) 104 (48) 112 (50) 106 (52)  
Magnetic resonance imaging/cholangiopancreatography  0.93      <0.001 
No / not stated 444 (82) 132 (81) 63 (83)   105 (74) 170 (78) 181 (81) 186 (91)  
Yes 98 (18) 31 (19) 13 (17)   36 (26) 48 (22) 42 (19) 18 (9)  
a Tumour status based on imaging or exploratory laparoscopy. 
b Chi-squared test. 
c Missing data: SES, n = 5; Tumour site, n = 21; Charlson comorbidity index, n = 4; Clinical stage , n = 43, First facility volume, n = 11; 
SES: socioeconomic status according to socio-economic index for areas of residence; ECOG: Eastern Cooperative Oncology Group; MDT: multidisciplinary team. 
 
